// App-Quantinova.ai

3245 : Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Researchers

Presenter

  • Maria Mateos

Principal Investigators

  • Sosana Delimpasi

  • Maryana Simonova

  • Ivan Spicka

  • Ludek Pour

  • Irina Kryachok

  • Maria Gavriatopoulou

  • Meletios A Dimopoulos

  • Halyna Pylypenko

  • Holger W Auner

  • Xavier Leleu

  • Vadim A Doronin

  • Ganna Usenko

  • Reuben Benjamin

  • Tuphan Kanti Dolai

  • Dinesh Kumar Sinha

  • Christopher P. Venner

  • Mamta Garg

  • Don A. Stevens

  • Hang Quach

  • Philippe Moreau

  • Moshe Y. Levy

  • Ashraf Z. Badros

  • Larry D. Anderson Jr

  • Nizar Bahlis

  • Thierry Facon

  • Michele Cavo

  • Yi Chai

  • Melina Arazy

  • Jatin Shah

  • Sharon Shacham

  • Michael G Kauffman

  • Paul G. Richardson

  • Sebastian Grosicki

Medical Centers

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY

  • Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece

  • Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine, Lviv, Ukraine

  • Charles University General Hospital in Prague, Prague, Czech Republic.

  • University Hospital Brno, Brno, Czech Republic

  • National Cancer Institute, Kiev, Ukraine

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Department of Hematology, Regional Treatment and Diagnostics Hematology Centre,Cherkasy Regional Oncology Centre,Cherkasy,Ucraina

  • Imperial College, London, United Kingdom

  • Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, France

  • Hematology Department, State Budget Healthcare Institution of Moscow, City Clinical Hospital #40 of Moscow Healthcare Department, Moscow, Russian Federation

  • City Clinical Hospital No. 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Hematology, NRS Medical College, Kolkata, India

  • Indira Gandhi Institue of Medical Sciences, Patna, India

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Norton Cancer Institute - St Matthews Campus, Louisville, KY

  • Melbourne Blood Specialist, East Melbourne, VIC, Australia

  • Department of Hematology, CHU Nantes, Nantes, France

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD

  • Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX

  • University of Calgary, Calgary, AB, Canada

  • CHRU de Lille, Service des maladies du sang, Lille, France

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Karyopharm Therapeutics, Newton, MA

  • Karyopharm Therapeutics, Newton, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Hematology and Cancer Prevention,Health Sciences Faculty, Medical University of Silesia,Katowice,Poland

Locations

  • Spain

  • United States

  • Greece

  • Ukraine

  • Czech Republic

  • United Kingdom

  • France

  • Russia

  • India

  • Canada

  • Australia

  • Italy

  • Poland

Companies

  • Karyopharm Therapeut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Selinexor

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved